(Q36680500)

English

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer

scientific article published on June 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

author name string

Comis RL

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Friedland DM

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

publication date

1 June 1995

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

12 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

S63-99

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxol: an antimitotic agent with a new mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxic and therapeutic activity of 4'-epi-doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of high-dose epirubicin in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of high dose epirubicin in unresectable non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of high-dose epirubicin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Diet and lung cancer. A review of the epidemiologic evidence in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dietary vitamin A and risk of cancer in the Western Electric study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant treatment of stage I lung cancer with high-dose vitamin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2980007-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(10)80007-8

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36680500&oldid=2179443254"